Last reviewed · How we verify
Cohort 3: HL217 Ophthalmic Solution QID — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cohort 3: HL217 Ophthalmic Solution QID (Cohort 3: HL217 Ophthalmic Solution QID) — Hanlim Pharm. Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cohort 3: HL217 Ophthalmic Solution QID TARGET | Cohort 3: HL217 Ophthalmic Solution QID | Hanlim Pharm. Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cohort 3: HL217 Ophthalmic Solution QID CI watch — RSS
- Cohort 3: HL217 Ophthalmic Solution QID CI watch — Atom
- Cohort 3: HL217 Ophthalmic Solution QID CI watch — JSON
- Cohort 3: HL217 Ophthalmic Solution QID alone — RSS
Cite this brief
Drug Landscape (2026). Cohort 3: HL217 Ophthalmic Solution QID — Competitive Intelligence Brief. https://druglandscape.com/ci/cohort-3-hl217-ophthalmic-solution-qid. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab